144 related articles for article (PubMed ID: 31432325)
21. Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Augustine CK; Toshimitsu H; Jung SH; Zipfel PA; Yoo JS; Yoshimoto Y; Selim MA; Burchette J; Beasley GM; McMahon N; Padussis J; Pruitt SK; Ali-Osman F; Tyler DS
Mol Cancer Ther; 2010 Jul; 9(7):2090-101. PubMed ID: 20571072
[TBL] [Abstract][Full Text] [Related]
22. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.
Wang YF; Jiang CC; Kiejda KA; Gillespie S; Zhang XD; Hersey P
Clin Cancer Res; 2007 Aug; 13(16):4934-42. PubMed ID: 17652623
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of transplantable melanoma cells to cytokines with regard to their spontaneous apoptosis.
Kozłowska K; Zarzeczna M; Cichorek M
Pathobiology; 2001; 69(5):249-57. PubMed ID: 12107342
[TBL] [Abstract][Full Text] [Related]
24. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
[TBL] [Abstract][Full Text] [Related]
25. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.
Berger Y; Bernasconi CC; Juillerat-Jeanneret L
Exp Biol Med (Maywood); 2006 Jun; 231(6):1111-9. PubMed ID: 16741059
[TBL] [Abstract][Full Text] [Related]
26. Diphenhydramine induces melanoma cell apoptosis by suppressing STAT3/MCL-1 survival signaling and retards B16-F10 melanoma growth in vivo.
Or CR; Su HL; Lee WC; Yang SY; Ho C; Chang CC
Oncol Rep; 2016 Dec; 36(6):3465-3471. PubMed ID: 27779705
[TBL] [Abstract][Full Text] [Related]
27. Camptothecin-induced death of amelanotic and melanotic melanoma cells in different phases of cell cycle.
Cichorek M
Neoplasma; 2011; 58(3):227-34. PubMed ID: 21391739
[TBL] [Abstract][Full Text] [Related]
28. Caffeine modulates growth and vitality of human melanotic COLO829 and amelanotic C32 melanoma cells: Preliminary findings.
Wrześniok D; Rzepka Z; Respondek M; Beberok A; Rok J; Szczepanik K; Buszman E
Food Chem Toxicol; 2018 Oct; 120():566-570. PubMed ID: 30056144
[TBL] [Abstract][Full Text] [Related]
29. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Ewald L; Dittmann J; Vogler M; Fulda S
Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941
[TBL] [Abstract][Full Text] [Related]
30. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells.
Mukherjee N; Lu Y; Almeida A; Lambert K; Shiau CW; Su JC; Luo Y; Fujita M; Robinson WA; Robinson SE; Norris DA; Shellman YG
Oncotarget; 2017 Jul; 8(29):46801-46817. PubMed ID: 27086916
[TBL] [Abstract][Full Text] [Related]
31. Antimelanoma activity of perphenazine and prochlorperazine in human COLO829 and C32 cell lines.
Otręba M; Pajor M; Warncke JD
Naunyn Schmiedebergs Arch Pharmacol; 2019 Oct; 392(10):1257-1264. PubMed ID: 31172223
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic BRAF signalling increases Mcl-1 expression in cutaneous metastatic melanoma.
McKee CS; Hill DS; Redfern CP; Armstrong JL; Lovat PE
Exp Dermatol; 2013 Nov; 22(11):767-9. PubMed ID: 24118207
[TBL] [Abstract][Full Text] [Related]
33. Mechanism of synergy of BH3 mimetics and paclitaxel in chronic myeloid leukemia cells: Mcl-1 inhibition.
Song T; Chai G; Liu Y; Xie M; Chen Q; Yu X; Sheng H; Zhang Z
Eur J Pharm Sci; 2015 Apr; 70():64-71. PubMed ID: 25596561
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis induced by Ginkgo biloba (EGb761) in melanoma cells is Mcl-1-dependent.
Wang Y; Lv J; Cheng Y; Du J; Chen D; Li C; Zhang J
PLoS One; 2015; 10(4):e0124812. PubMed ID: 25860257
[TBL] [Abstract][Full Text] [Related]
35. MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor.
Xiao Y; Nimmer P; Sheppard GS; Bruncko M; Hessler P; Lu X; Roberts-Rapp L; Pappano WN; Elmore SW; Souers AJ; Leverson JD; Phillips DC
Mol Cancer Ther; 2015 Aug; 14(8):1837-47. PubMed ID: 26013319
[TBL] [Abstract][Full Text] [Related]
36. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
Besbes S; Pocard M; Mirshahi M; Billard C
Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
[TBL] [Abstract][Full Text] [Related]
37. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
38. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting.
Slomp A; Moesbergen LM; Gong JN; Cuenca M; von dem Borne PA; Sonneveld P; Huang DCS; Minnema MC; Peperzak V
Blood Adv; 2019 Dec; 3(24):4202-4214. PubMed ID: 31856269
[TBL] [Abstract][Full Text] [Related]
39. Confounding off-target effects of BH3 mimetics at commonly used concentrations: MIM1, UMI-77, and A-1210477.
Mallick DJ; Soderquist RS; Bates D; Eastman A
Cell Death Dis; 2019 Feb; 10(3):185. PubMed ID: 30796196
[TBL] [Abstract][Full Text] [Related]
40. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
